Efficacy and Safety of Secukinumab in Patients with Spondyloarthritis and Enthesitis at the Achilles Tendon: 52-weeks Results from a Randomized, Placebo-controlled Phase 3b Trial

被引：0

作者：

Behrens, Frank ^{[1
,2
]}

Sewerin, Philipp ^{[3
,4
]}

De Miguel, Eugenio ^{[5
]}

Patel, Yusuf ^{[6
]}

Batalov, Anastas ^{[7
]}

Dokoupilova, Eva ^{[8
,9
]}

Kleinmond, Christine ^{[10
]}

Pournara, Effie ^{[11
]}

Shekhawat, Ankita ^{[12
]}

Jentzsch, Claudia ^{[13
]}

Wiedon, Annette ^{[14
]}

Baraliakos, Xenofon ^{[15
]}

机构：

[1] Goethe Univ, CIRI Rheumatol, Frankfurt, Germany

[2] Goethe Univ, Fraunhofer TMP, Frankfurt, Germany

[3] Univ Hosp Dusseldorf, Dept Rheumatol, Dusseldorf, Germany

[4] Univ Hosp Dusseldorf, Hiller Res Unit, Dusseldorf, Germany

[5] Hosp Univ La Paz, Dept Rheumatol, Madrid, Spain

[6] Hull Univ Teaching Hosp, Kingston Upon Hull, East Yorkshire, England

[7] Med Univ Plovdiv, Univ Hosp Kaspela, Plovdiv, Bulgaria

[8] Med Plus Sro, Uherske Hradiste, Czech Republic

[9] Univ Vet & Pharmaceut Sci, Fac Pharm, Dept Pharmaceut, Uherske Hradiste, Czech Republic

[10] ClinProject GmbH, Eurasburg, Germany

[11] Novartis Pharma AG, Basel, Switzerland

[12] Novartis Healthcare Private Ltd, Hyderabad, Telangana, India

[13] Novartis Pharma GmbH, Nurnberg, Germany

[14] Novartis Pharma GmbH, Nurnberg, Germany

[15] Ruhr Univ Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany

来源：

ARTHRITIS & RHEUMATOLOGY | 2020年 / 72卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0882

引用

页数：3

共 50 条

[21] Efficacy and safety of adalimumab in patients with moderate to severe hidradenitis suppurativa: Results from PIONEER II, a phase 3, randomized, placebo-controlled trial
Jemec, Gregor
Gottlieb, Alice
Forman, Seth
Giamarellos-Bourboulis, Evangelos
Reguiai, Ziad
Gu, Yihua
Okun, Martin
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB45 - AB45
[22] Secukinumab Provides Sustained Improvements in Psoriatic Arthritis: 2-Year Efficacy and Safety Results from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial
Mease, Philip J.
McInnes, Iain B.
Kirkham, Bruce
Kavanaugh, Arthur
Rahman, Proton
van der Heijde, Desiree
Landewe, Robert B. M.
Nash, P.
Pricop, Luminita
Wang, Zailong
Mpofu, Shephard
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[23] Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study
Van Voorhees, Abby S.
Gold, Linda Stein
Lebwohl, Mark
Strober, Bruce
Lynde, Charles
Tyring, Stephen
Cauthen, Ashley
Sofen, Howard
Zhang, Zuoshun
Paris, Maria
Wang, Yao
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (01) : 96 - 103
[24] Efficacy and safety of infliximab in patients with ankylosing spondylitis - Results of a randomized, placebo-controlled trial (ASSERT)
van der Heijde, D
Dijkmans, B
Geusens, P
Sieper, J
DeWoody, K
Williamson, P
Braun, K
Breban, M
Burmester, G
Clark, M
Deadhar, A
Douga-dos, M
Edwards, W
Gaston, J
Inman, R
Kellner, H
Leirisalo-Repo, M
Maksymowych, W
Moreland, L
Peloso, P
Reveille, J
Ritchlin, C
Schneider, M
Smith, D
Steinfeld, S
Veys, E
de Vlam, K
Zeidler, H
ARTHRITIS AND RHEUMATISM, 2005, 52 (02): : 582 - 591
[25] Secukinumab Provides Significant Improvement of Spinal Pain and Lowers Disease Activity in Patients with Axial Spondyloarthritis: 24-week Results from a Randomized Controlled Phase 3b Trial
Poddubnyy, Denis
Pournara, Effie
Zielinska, Agnieszka
Baranauskaite, Asta
Munoz Jimenez, Alejandro
Sadhu, Sanchayita
Schulz, Barbara
Rissler, Michael
Perella, Chiara
Marzo-Ortega, Helena
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[26] EFFICACY OF SECUKINUMAB AND HLA-B27 SUBTYPES: RESULTS FROM A PHASE 3B RANDOMISED CONTROLLED TRIAL IN AXIAL SPA
Marzo-Ortega, Helena
Poddubnyy, Denis
Pournara, Effie
Schulz, Barbara
Deodhar, Atul
Baraliakos, Xenofon
RHEUMATOLOGY, 2022, 61 : I19 - I19
[27] Efficacy of adalimumab in nail psoriasis by baseline subgroups, and overall safety from first 26 weeks of a phase 3, randomized, placebo-controlled trial
Rich, Phoebe A.
Baker, Christopher S.
Valenzuela, Fernando
Rey, Maria P.
Geng, Ziqian
Gu, Yihua
Servin, Ofelia Reyes
Poulin, Yves
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB200 - AB200
[28] Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial
Sigurgeirsson, Bardur
Browning, John
Tyring, Stephen
Szepietowski, Jacek C.
Rivera-Diaz, Raquel
Effendy, Isaak
Keefe, Deborah
Bruin, Gerard
Paguet, Bertrand
Fu, Rong
Hampele, Isabelle
Reinhardt, Maximilian
Patekar, Manmath
DERMATOLOGIC THERAPY, 2022, 35 (03)
[29] The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)
Reich, K.
Gooderham, M.
Green, L.
Bewley, A.
Zhang, Z.
Khanskaya, I.
Day, R. M.
Goncalves, J.
Shah, K.
Piguet, V.
Soung, J.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (03) : 507 - 517
[30] EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL
Deodhar, A.
Van den Bosch, F.
Poddubnyy, D.
Maksymowych, W. P.
Van der Heijde, D.
Kim, T. H.
Kishimoto, M.
Duan, Y.
Li, Y.
Pangan, A.
Wung, P.
Song, I. H.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 9 - 10

← 1 2 3 4 5 →